EUCTR2009-012367-34-HU进行中（未招募）1 期
A Phase 3, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of Peramivir Administered Intravenously in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents who are Hospitalized due to Serious Influenza.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 306
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age =12 years of age, male or female.
- •2. Able to provide informed consent, or for whom consent may be provided by guardian, unless informed consent provided by a guardian or a legally authorized representative is not consistent with applicable local or ethical concerns, procedures, directives and/or guidelines.
- •3. Subject must have at least one of the following clinical presentations:
- •a. Oral temperature > 38.0 °C (>100.4 °F), =38.6°C (101.4 °F) tympanic or rectal
- •b. Oxygen saturation <92%, OR
- •c. Two out of the following three vital signs:
- •Respiration rate >24/minute
- •Heart rate >100/minute
- •Systolic BP <90 mmHg
- •4. Presence of at least one respiratory symptom (cough, sore throat, or nasal congestion) of any severity (mild, moderate, or severe).
- •5. Presence of at least one constitutional symptom (headache, myalgia, feverishness, or fatigue) of any severity (mild, moderate, or severe).
- •6. Onset of illness no more than 72 hours before presentation. Note: Time of onset of illness is defined as either (1) the time when the temperature was first measured as elevated, OR (2) the time when the subject experienced the presence of at least one respiratory symptom AND the presence of at least one constitutional symptom.
- •7. Either:
- •Severity of illness that, in the Investigator’s judgment, justifies hospitalization of the subject for supportive care.
- •Presence of one or more of the following factors:
- •Age =60 years.
- •Presence of chronic obstructive pulmonary disease (COPD) or other chronic lung disease requiring daily pharmacotherapy.
- •Current history of congestive heart failure or angina.
- •Presence of diabetes mellitus, clinically stable or unstable.
- •Transcutaneous oxygen saturation <94% without supplemental oxygen for at least 5 minutes, or a medically significant decrease in oxygen saturation from an established baseline value (an investigative site at altitude >2000 ft above sea level will utilize different criteria for oxygen saturation).
- •History of chronic renal impairment not requiring dialysis.
- •Serum creatinine > 2.0 mg/dL.
- •8. Diagnosis of Influenza by satisfying one of the following:
- •a. Clinical Influenza with Positive Diagnostic Test. Subjects who have a positive rapid antigen test (RAT) for influenza A and/or influenza B (using a Sponsor-approved test kit), or positive test (using other methodology) for influenza A and/or B virus antigen or RNA performed in a clinical laboratory at the screening/enrollment evaluation are eligible for enrollment.
- •b. Clinical Influenza with Negative Rapid Antigen Test (RAT). Subjects with a negative RAT or other clinical laboratory test may be enrolled once the site has been approved by the Sponsor to enroll such subjects, based on documentation of an outbreak of influenza in the community. An influenza outbreak may be documented in the catchment area of the hospital via one of the following methods: 1) local confirmation of influenza A or B infection in the current influenza season by a) the institution’s local laboratory, or b) the local public health system, or c) the national public health system, or d) a laboratory of a recognized multinational influenza surveillance scheme such as the European Influenza Surveillance Scheme (EISS); 2) prior enrollment of a RAT positive subject into this study at the same institution in the current influenza season.
- •9. Females must fulfill one of t
排除标准
- •1. Subjects who have developed clinical manifestations of influenza after having been hospitalized for greater than 24 hours for a condition other than confirmed or suspected influenza.
- •2. Treatment with any dose(s) of rimantadine, amantadine, ribavirin, zanamivir, or oseltamivir in the previous 7 days.
- •3. Blood platelet count of < 20 x 1,000,000,000/L.
- •4. Serum bilirubin > 6 mg/dL at time of screening evaluation.
- •5. Serum ALT or AST > 5 times the upper limit of normal at time of screening evaluation.
- •6. Congestive heart failure of NYHA Class III or Class IV functional status.
- •7. Requirement for vasopressor support to maintain satisfactory hemodynamic status at time of screening evaluation.
- •8. Serum creatinine > 5.0 mg/dL at time of screening evaluation.
- •9. Subjects who require peritoneal dialysis or hemofiltration.
- •10. Altered neurologic status as defined by a Glasgow Coma Score of = 9, unless medically induced.
- •11. Females who are pregnant (positive urine or serum pregnancy test at screening evaluation) or lactating.
- •12. Actively undergoing systemic chemotherapy or radiotherapy treatment for a malignancy.
- •13. Prior hematopoietic stem cell transplantation or solid organ transplant during the previous 4 months.
- •14. HIV infection with a known CD4 count < 200 cells/mm3 unless on a stable highly active antiretroviral regimen (HAART) for at least 6 months.
- •15. Presence of a pre-existing chronic infection that is undergoing or requiring medical therapy (eg, tuberculosis). Subjects with chronic osteomyelitis are not excluded.
- •16. Presence of any pre-existing illness that, in the opinion of the investigator, would place the subject at an unreasonably increased risk through participation in this study.
- •17. Previous treatment with intravenous or intramuscular peramivir.
- •18. Participation as a subject in any study of an experimental treatment for any condition within the 30 days prior to the time of the screening evaluation.
- •19. Subjects who, in the judgment of the investigator, will be unlikely to comply with the requirements of this protocol.
研究者
相似试验
进行中（未招募）
不适用
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Trial of AMG 479 or Placebo in Combination with Gemcitabine as First-line Therapy for Metastatic Adenocarcinoma of the Pancreas - GAMMAmetastatic adenocarcinoma of the pancreasMedDRA version: 12.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticMedDRA version: 12.1Level: LLTClassification code 10033606Term: Pancreatic cancer non-resectableEUCTR2010-020398-18-SIAmgen Inc.825
进行中（未招募）
1 期
Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn’s DiseaseModerately to Severely Active Crohn’s DiseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2017-004294-14-ESCelgene International II Sàrl485
进行中（未招募）
不适用
Phase 3 Study of SAR302503 in Intermediate-2 and High risk patients with Myelofibrosis de riesgo intermedio de nivel 2 o altoPrimary myelofibrosis, post-polycythemia vera myelofibrosis, or post- essential thrombocythemia myelofibrosisMedDRA version: 14.0Level: LLTClassification code 10018864Term: Haematopoietic neoplasm NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001897-25-ESsanofi-aventis recherche & développement225
已完成
3 期
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn*s DiseaseNL-OMON54627Celgene International II Sàrl2
进行中（未招募）
不适用
Phase 3 Study of SAR302503 in Intermediate-2 and High risk patients with MyelofibrosisPrimary myelofibrosis, post-polycythemia vera myelofibrosis, or post- essential thrombocythemia myelofibrosisMedDRA version: 16.1Level: LLTClassification code 10018864Term: Haematopoietic neoplasm NOSSystem Organ Class: 100000004864EUCTR2011-001897-25-DEsanofi-aventis recherche & développement225